

- How do I proceed when basic data on diagnosis and prognosis are unavailable?
- Would imaging help with diagnosis?
- What are the most appropriate investigations in this case and how should I interpret them in order to proceed?
- Which of the available drugs should I use and what do I do if they're not NICE-approved?
- Am I unnecessarily exposing the patient to dangerous interventions?
- How do I weigh risks against benefits for this particular patient?
- Am I being over-optimistic about the clinical benefits of the latest research I've read, and is it 'fit for purpose' in this patient?
- How do I take account of the patient's values, beliefs and fears when making my suggestions and decisions?
- How do I satisfy myself – and others – than I'm fulfilling my duty of care to this patient?
- How do I best respond when the patient asks: 'The study I read about on the internet said the treatment you're suggesting to me is likely on average to do more harm than good. But what does 'on average' mean for me?'
- How do I best respond when the patient asks: 'The nurse and support group people said the treatments can sometimes cause severe side-effects. Should I take the risk?'
- How do I best respond when the patient asks: 'How long can I expect to stay well? How can I help myself?'
- At what point should I refer my patient to other members of the multi-disciplinary team?

MASTERCLASS IN ADVANCED CANCER MEDICINE SKIN CANCERS - 2008

Expert Panel

Dr. Jerry Marsden (Dermatology)(Chairman)
Consultant Dermatologist, University Hospital Birmingham &
Immediate Past Secretary, Melanoma Study Group

Professor Barry Hancock (Clinical Oncology)
Professor of Clinical Oncology, University of Sheffield

Professor Martin Gore (Medical Oncology)
Professor of Cancer Medicine, The Royal Marsden Hospital, London

Dr. Paul Nathan (Medical Oncology)
Consultant Medical Oncologist, Mount Vernon Hospital, Middlesex

Professor Chris Bunker (Dermatology)
Professor of Dermatology, Chelsea & Westminster Hospital, London

Dr. Jonathan Bowling (Dermatology)
Consultant Dermatologist, Churchill Hospital, Oxford

Mr. Barry Powell (Plastic Surgery)
Consultant Plastic Surgeon, St. George's Hospital, London

Professor Meirion Thomas, (Surgery)
Professor of Surgical Oncology, The Royal Marsden Hospital, London

Professor Martin Cook (Pathology)
Consultant Pathologist, Royal Surrey County Hospital, Guildford

CLINICAL PROGRAMME

9.40 am COFFEE AND REGISTRATION

10.20 am Welcoming address
Dr. Jerry Marsden
Chairman of the Expert Panel

APPLYING CURRENT KNOWLEDGE TO INDIVIDUAL PATIENTS: CASE-BASED ILLUSTRATIONS OF EVIDENCE-BASED SKIN CANCERS MANAGEMENT

MORNING CASES

- Patient 1**
- 10.30 am (a) Presentation of patient history and characteristics
(b) Discussion of investigation and treatment options with reference to the modern literature and international consensus
(c) Consensus statement on optimal treatment strategy
- Patient 2**
- 11.00 am (a) Presentation of patient history and characteristics
(b) Discussion of investigation and treatment options with reference to the modern literature and international consensus
(c) Consensus statement on optimal treatment strategy
- Patient 3**
- 11.30 am (a) Presentation of patient history and characteristics
(b) Discussion of investigation and treatment options with reference to the modern literature and international consensus
(c) Consensus statement on optimal treatment strategy

- Patient 4**
- 12 noon (a) Presentation of patient history and characteristics
(b) Discussion of investigation and treatment options with reference to the modern literature and international consensus
(c) Consensus statement on optimal treatment strategy
- Patient 5**
- 12.30 pm (a) Presentation of patient history and characteristics
(b) Discussion of investigation and treatment options with reference to the modern literature and international consensus
(c) Consensus statement on optimal treatment strategy
- 1.00 pm LUNCHEON
- AFTERNOON CASES**
- Patient 6**
- 1.40 pm (a) Presentation of patient history and characteristics
(b) Discussion of investigation and treatment options with reference to the modern literature and international consensus
(c) Consensus statement on optimal treatment strategy
- Patient 7**
- 2.10 pm (a) Presentation of patient history and characteristics
(b) Discussion of investigation and treatment options with reference to the modern literature and international consensus
(c) Consensus statement on optimal treatment strategy
- Patient 8**
- 2.40 pm (a) Presentation of patient history and characteristics
(b) Discussion of investigation and treatment options with reference to the modern literature and international consensus
(c) Consensus statement on optimal treatment strategy
- 3.10 pm AFTERNOON TEA
- Patient 9**
- 3.30 pm (a) Presentation of patient history and characteristics
(b) Discussion of investigation and treatment options with reference to the modern literature and international consensus
(c) Consensus statement on optimal treatment strategy
- Patient 10**
- 4.00 pm (a) Presentation of patient history and characteristics
(b) Discussion of investigation and treatment options with reference to the modern literature and international consensus
(c) Consensus statement on optimal treatment strategy
- Patient 11**
- 4.30 pm (a) Presentation of patient history and characteristics
(b) Discussion of investigation and treatment options with reference to the modern literature and international consensus
(c) Consensus statement on optimal treatment strategy
- Patient 12**
- 5.00 pm (a) Presentation of patient history and characteristics
(b) Discussion of investigation and treatment options with reference to the modern literature and international consensus
(c) Consensus statement on optimal treatment strategy
- 5.30 pm Chairman's Summary & Close of Masterclass

Masterclass in Advanced Cancer Medicine - Skin Cancers (15 December 2008)

NB: Please read the section on General Information before completing this form in BLOCK CAPITALS

Registration fee: Medical staff: £149 (126.81+22.19 VAT) or 'early bird' £129 (109.79+19.21 VAT) for registrations received before 19 September 2008

Nursing staff: £129 (109.79+19.21 VAT) or 'early bird' £99 (84.26+14.74 VAT) for registrations received before 19 September 2008

Please pay: **Key Advances Ltd**

Title (Mr/Mrs/Ms/Dr/Prof) Surname

Forename (s)

Post

Department

Hospital

Address for correspondence

Town

County Postcode

Daytime Tel no. Fax no.

E-mail

Any special dietary requirements

Please tick this box if you do not wish to receive further information about educational events in the UK Key Advances in Clinical Practice Series

Please return this form with a cheque made payable to **Key Advances Ltd** to: Mr Francesco Scordamaglia, Administrator, UK Key Advances Series, P.O. Box LB48 Mount Pleasant Mail Centre, Farringdon Road, London EC1A 1LB. **Tel: 020 7735 7061;** **Fax: 020 3242 0042; email: francesco@keyadvances.org.uk**

Key Advances Limited registered in England number 03504107 VAT Reg. No. 710581365. Registered Office: Unit 20, West Building, London SE11 5JH, UK

About the Masterclass

The Masterclass has been designed specifically to illustrate how 'general research evidence' derived from clinical trials and meta-analysis and other major studies published in the literature can be applied to the care of individual patients. As such, the masterclass will provide direct lessons in 'evidence-based' cancer medicine in the management of the patient with dermatological malignancies. Following a description of the clinical characteristics of the presenting patient, detailed and highly interactive discussion will take place on the range of treatment options with direct reference to current evidence and published studies, concluding with a consensus statement on optimal management.

Who should attend?

Consultants in Dermatology, Plastic Surgery, Medical, Clinical and Surgical Oncology, Histopathology and trainees/non-consultant career grades across these specialties, Oncology and Dermatology Nurse Specialists, Oncology Pharmacists, members of the pharmaceutical industry and all those colleagues with a responsibility for or interest in the effective management of the patient with skin cancer.

Venue

The Julian Bloom Lecture Theatre, Royal Marsden Hospital, Fulham Road, London SW3. Full details and directions will be provided to delegates on receipt of a completed Registration Form

Fee and payment

The fee for attendance is £149 (special rate for nurses and pharmacists £129). Fees include lunch, mid session refreshments and all masterclass materials. Cheques should be made payable to Key Advances Ltd and sent to the full address shown at the bottom of the Registration Form overleaf. Payments from abroad should be by international bankers' draft or money order in pounds sterling drawn on a UK bank.

Enquiries

All enquiries in relation to the administrative aspects of this masterclass should be made to Mr. Francesco Scordamaglia on 020 - 7735 - 7061 or fax 020 - 3242 - 0042 or e-mail francesco@keyadvances.org.uk. Enquiries of an academic or clinical nature may be made to Professor Andrew Miles on 020 - 7091 - 9674 or e-mail andrew.miles@keyadvances.org.uk

Cancellations

Cancellations will only be accepted in writing. A refund less an administrative charge of £25.00 will be given on cancellations made by 14 November 2008. Thereafter the full fee is payable. Substitutions may be made at any time. Please note that cheques returned by the bank will incur an administrative charge of £20.00. No refunds can be given after 14 November 2008 for cancellations arising from industrial action or acts of terrorism.

CPD accreditation

Attendance at this masterclass carries 6 CPD points.

Data Protection Act

Your name, current postal and hospital address (or correspondence address given if no current hospital post) will be included in the list of participants which will be issued to delegates and speakers

Accommodation

Details of a range of high quality London hotels within easy reach of the Royal Marsden Hospital London will be sent to colleagues on receipt of the delegate Registration Form

Note from Professor Andrew Miles, Director of the Series

The 2nd National UK Key Advances Update Symposium on the Effective Management of Malignant Melanoma will be held in London on 17 November 2008. For details contact Francesco Scordamaglia on 020-7735-7061 or e-mail: francesco@keyadvances.org.uk

www.keyadvances.org.uk

MASTERCLASS IN ADVANCED CANCER MEDICINE

Skin Cancers - 2008 (Inaugural National Update)

LONDON 15 DECEMBER 2008

6-CPD/Highly Interactive/Wide range of difficult, unusual and challenging clinical cases

- Learn about and discuss the latest medical evidence published in the peer-reviewed literature and presented at international conferences
- Learn and discuss how to proceed when basic data on diagnosis and prognosis are unavailable
- Learn and discuss how to select appropriate investigations, how to interpret their results and how they can change odds and management
- Learn and discuss how to select appropriate therapies and to weigh risks and benefits in the individual case and how to explain their effects to informed and uninformed patients
- Learn and discuss how to assess the 'fitness for purpose' of recent 'general research evidence' from trials and meta-analyses and how to assess its suitability for application in the individual case
- Learn and discuss how to integrate patient values, beliefs and fears in the making of good clinical decisions



ecancermedicalsience

Venue

The Royal Marsden Hospital Lecture Theatre, London SW3